Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

ORIGINAL ARTICLE
[Download PDF
 
Year : 2021  |  Volume : 67  |  Issue : 3  |  Page : 134-138  

A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic

NJ Gogtay, HJ Sheth, MR Maurya, MN Belhekar, UM Thatte 
 Department of Clinical Pharmacology, Seth G. S. Medical College and K. E. M. Hospital, Mumbai, Maharashtra, India

Correspondence Address:
N J Gogtay
Department of Clinical Pharmacology, Seth G. S. Medical College and K. E. M. Hospital, Mumbai, Maharashtra
India

Abstract

Objectives: We evaluated the extent of consent declines and consent withdrawals during the COVID-19 pandemic as seen in published randomized controlled trials (RCTs) and compared it with non-COVID-19 RCTs published at the same time and two historical controls. Methods: PubMed/Medline only was searched using key-word “COVID-19” and “RCTs” separately, and filtered for COVID-19 RCTs and non-COVID-19 RCTs respectively, published during a nine-month period (1 Feb - 1 Nov 2020). Exclusions were study protocols, observational studies, interim analysis of RCT data and RCTs with missing data. Primary outcome measures were the proportion of consent declines and consent withdrawals as percentage of total participants screened and randomized respectively in COVID-19 RCTs. We compared consent declines and consent withdrawals of COVID-19 RCTs with non-COVID-19 RCTs and two earlier studies on the same topic that served as historical controls (non-pandemic setting). Results: The search yielded a total of 111 COVID-19 RCTs and 49 non-COVID-19 RCTs. Of these, 39 (35.13%) COVID-19 RCTs and 11 (22.45%) non-COVID-19 RCTs were finally analysed. A total of 770/17759 (4.3%) consent declines and 100/7607 (1.31%) consent withdrawals were seen in 39 COVID-19 RCTs. A significant difference was observed in consent declines between COVID-19 vs non-COVID-19 RCTs [4.3% vs 11.9%, p < 0.0001] and between COVID-19 RCTs vs two historical controls [(4.3% vs 8.6%, p < 0.0001) and (4.3% vs 21.1%, p < 0.0001), respectively]. Conclusion: RCTs conducted during the COVID-19 pandemic appear to have significantly lower consent declines relative to non-COVID-19 RCTs during pandemic and RCTs conducted in non-pandemic settings.



How to cite this article:
Gogtay N J, Sheth H J, Maurya M R, Belhekar M N, Thatte U M. A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic.J Postgrad Med 2021;67:134-138


How to cite this URL:
Gogtay N J, Sheth H J, Maurya M R, Belhekar M N, Thatte U M. A literature review of consent declines and consent withdrawals in randomized controlled trials conducted during the COVID-19 pandemic. J Postgrad Med [serial online] 2021 [cited 2022 Jun 29 ];67:134-138
Available from: https://www.jpgmonline.com/text.asp?2021/67/3/134/323981


Full Text



 Background



The informed consent process, a metric of autonomy, confers upon participants the right to decline or accept participation in a study in equal measure.[1] An analysis of consent declines and consent withdrawals can thus serve as a useful index of the adequacy of the informed consent process.[2] As the COVID-19 pandemic continues to ravage the world, several studies have been published in this area and continue to be conducted both in patients (with repurposed or experimental treatments),[3],[4],[5],[6] and normal healthy participants (vaccines or drugs for prophylaxis),[7],[8],[9] in an attempt to treat or mitigate the course of the disease.

The informed consent process during a pandemic can be exceedingly difficult as patients are not likely to have access to medication, are likely to be desperate to the point of being reckless [in the face of uncertainty] and suffer from therapeutic misconception.[10] They may also be too sick to give consent themselves. Their legally acceptable representatives (LAR) also may be ill themselves or quarantined when families as a cluster are affected.

Against this backdrop, a literature review of consent declines and consent withdrawals as seen in published literature [COVID-19 RCTs] can help us understand the extent to which participants decline participation or withdraw consent in clinical research during a pandemic and hence the present study was envisaged. A secondary objective was to compare the two stated metrics with similar data from non-COVID-19 RCTs published during the pandemic (same time frame) as well as historical controls (studies done earlier during a non-pandemic time).

 Materials and Methods



Ethics

The study [EC/OA-157/2020] was accorded a waiver by Institutional Ethics Committee.

Case definitions used for the study

A consent decline was defined as that occurring at the time of screening,[11] while a consent withdrawal was defined as one that occurred after the participant signed the informed consent document.[12] Thus, the denominator for consent declines was the total number of participants screened whereas for consent withdrawals it was the total number of participants randomized.

Search strategy and time period

COVID-19 RCTs: PubMed/Medline was searched using the keywords “RCTs” AND “COVID-19” for English language publications.non-COVID-19 RCTs: PubMed/Medline was searched using the keywords “RCTs”, after filtering out all COVID-19 RCTs. A nine-month time period (1 Feb - 1 Nov 2020) was chosen. The search was done independently by two authors and verified by the senior authors.

Selection criteria

For both types of RCTs; study protocols, observational studies, interim analysis of data, studies on e-learning for COVID-19 and RCTs where data on consent declines and consent withdrawals was missing were excluded. This gave us only RCTs with interventions for analysis.

Outcome measures

The primary outcome measures were a) the proportion of consent declines as a percentage of total participants screened and b) the proportion of consent withdrawals as a percentage of total participants randomized in COVID-19 RCTs. The secondary outcome measures were comparison of consent declines (and consent withdrawals where applicable) of the COVID-19 RCTs with i) non-COVID-19 RCTs and ii) two historical controls [see below]. Within a given COVID-19 RCT, we also compared the stated metrics for therapeutic versus prophylactic interventions and disease severity of COVID-19,[13] (mild,[3] and moderate-severe,[5],[6]). Only consent withdrawals were compared for interventional arm versus standard of care/best supportive care arms.

Historical controls

Two earlier studies published on a similar topic were chosen as historical controls. The first study was an analysis of consent declines amongst RCTs published in three leading, high impact factor medical journals and thus similar to the present study.[2] The second was an analysis of consent declines in ten studies conducted at a tertiary referral centre and thus disparate.[14]

Statistical analysis

Both descriptive and inferential statistics were used. Categorical data (proportion of consent declines and consent withdrawals) are expressed as percentages. The number of consent declines and withdrawals (quantitative data) are expressed as median (range). The proportion of consent declines and consent withdrawals in COVID-19 RCTs relative to non-COVID-19 RCTs as well as the proportion of consent declines in COVID-19 RCTs relative to the historical controls were analysed using the Chi-square test. Also, the proportion of consent declines and consent withdrawals in COVID-19 RCTs with mild disease relative to those with moderate-severe disease were analysed using the Chi-square test. All analyses were done at 5% significance using Epi Info 7.0.

 Results



Demographic data

As of 17th November 2020, a total of 160 RCTs were available on PubMed/Medline. Of these, 111 were COVID-19 RCTs and the remaining 49 were non-COVID-19 RCTs.

COVID-19 RCTs

Of the 111 RCTs, 72/111 (64.86%) were excluded. A total of 39/111 (35.13%) RCTs formed the final sample. Of these, 36/39 (92.3%) were RCTs with repurposed drugs for COVID-19 patients whereas 2/39 (5.1%) were vaccine studies and 1/39 (2.5%) was a study that used hydroxychloroquine (HCQ) as prophylaxis [in normal, healthy participants] [Table 1]. The disease severity of COVID-19 in 36/39 (92.3%) RCTs was categorized as mild (8/36, 22.2%) and moderate-severe (28/36, 77.8%).{Table 1}

Non-COVID-19 RCTs

Out of 49 RCTs, 38/49 (77.56%) RCTs were not analysed as they met exclusion criteria. A total of 11/49 (22.45%) RCTs formed the comparison group [Table 1].

Analysis of consent declines and consent withdrawals

COVID-19 RCTs

A total of 770/17759 (4.3%) consent declines and 100/7607 (1.31%) consent withdrawals were seen in 39/39 and 37/39 RCTs respectively [Table 2]. The median (range) consent declines and consent withdrawals were 2 (0-238) and 1 (0-19) respectively.{Table 2}

Non-COVID-19 RCTs

Among 11 (22.45%) RCTs, total consent declines and consent withdrawals noted were 1172/9867 (11.9%) and 102/6155 (1.65%) respectively [Table 2].

Comparison of consent declines and consent withdrawals in COVID-19 RCTs vs non-COVID-19 RCTs

A statistically significant difference was seen between the two groups with fewer consent declines in the COVID-19 RCTs [4.3% vs 11.9%, p < 0.0001]. On the contrary, the consent withdrawals between two groups were not statistically significant [1.31% vs 1.65%, p = 0.11] [Table 2].

Comparison of consent declines in COVID-19 RCTs with historical controls

When the consent declines in COVID-19 RCTs were compared with the first historical control (consent declines in RCTs published in three leading biomedical journals), it was seen that there was a statistically significant difference between the two groups with fewer consent declines seen in COVID-19 RCTs [4.3% vs 8.6%, p < 0.0001]. Likewise, fewer consent declines were seen in COVID-19 RCTs relative to another historical control that evaluated consent declines in n = 10 studies at a tertiary centre. The consent decline rate of 4.3% with the former was much less than the consent decline rate of 21.1% with the latter [p < 0.0001] [Table 2].

Miscellaneous analysis

Consent declines and consent withdrawals in COVID-19 RCTs based on disease severity

When the consent declines and consent withdrawals in COVID-19 RCTs with mild disease relative to those with moderate-severe disease were compared, a statistically significant difference was seen with fewer consent declines and consent withdrawals in the those with mild disease relative to moderate-severe disease, [0.4% vs 4.53%, p < 0.001] and [0.2% vs 1.85%, p < 0.0001] respectively.

Comparison of consent withdrawals in the standard of care/best supportive care vs interventional arms in COVID-19 RCTs

A total of 100/7607 participants (1.31%) withdrew consent in 37/39 RCTs. Consent withdrawals were 0.8% in the standard of care/best supportive care arm vs 1.34% in interventional arm [p = 0.01].

Nature of study and extent of consent declines and consent withdrawals in COVID-19 RCTs

In 36/39 (92.3%) therapeutic RCTs, a total of 352/10466 (3.4%) consent declines and 82/5216 (1.6%) consent withdrawals were noted. Similarly, 240/7293 (3.3%) consent declines and 8/2406 (0.34%) consent withdrawals were noted in 3/39 (7.6%) RCTs that had prophylactic interventions. Some RCTs had a zero percent consent decline rate (one vaccine trial and 14 trials with repurposed drugs),[7],[15],[16] while others such as Hydrocortisone in severe COVID-19,[17] and HCQ prophylaxis,[9] had a much higher consent declines at 16% and 5% respectively.

 Discussion



The present literature review evaluated consent declines and consent withdrawals in published COVID-19 RCTs (PubMed/Medline only) and showed a much lower consent decline rate in these studies (4.3%) relative to non-COVID-19 RCTs during a pandemic (11.9%) and the two historical controls (audits) conducted in a non-pandemic setting at 8.6%,[2] and 21%,[14] respectively indicating that participants are less likely to decline consent in COVID-19 RCTs conducted during the pandemic.

In COVID-19, to date, there is no effective anti-viral drug and treatments are largely repurposed. In many countries, depending upon the status of patents on these repurposed drugs (for example: Remdesivir, Sofosbuvir)[18],[19]; patients may or may not be able to afford the treatment. Thus, clinical research remains the best opportunity to access these treatments.

The consent declines (11.9%) in non-COVID-19 RCTs are almost thrice that of 4.3% as seen in COVID-19 RCTs during a pandemic. This strengthens our hypothesis of desperation, lack of access to medication and therapeutic misconception which may have contributed to lower consent declines in COVID-19 RCTs.

In the present literature review, consent declines in mild COVID-19 disease (0.4%) were found to be almost four times lower than those with moderate-severe disease (4.53%). Similarly, fewer consent withdrawals were noted in mild COVID-19 disease (0.2%) relative to those with moderate-severe disease (1.85%). This finding is not very easy to explain. One possibility is that with mild disease, the decision making was done by the patient himself while with moderate and severe disease, both patients and LARs may have been involved in the decision making leading to the difference seen.

Both historical controls were audits at our centre which is a high-volume research facility at a tertiary referral hospital in Western India. The first historical control was an evaluation of consent declines in RCTs (as seen in the CONSORT flow charts) published in three leading biomedical journals which is a better control for the present literature review as it is on similar lines.[2] The consent decline rates of 8.6%,[2] are twice that of 4.3% as seen in COVID19 RCTs in a pandemic setting reaffirming the fact that consent declines indeed seem lower in a pandemic. The second historical control was an audit where analysis of consent declines in ten studies was conducted at our centre.[14] Here, the nature of studies were phase I-IV studies with pharmacokinetic, safety, efficacy and bioequivalence analysis (three observational and seven interventional) which showed a consent decline rate of 21.1%, ranging from 0-64%.[14] This is both a strength (done during a non-pandemic setting) and a limitation (not all studies were RCTs) of the second historical control.

While the overall consent decline rate in COVID-19 RCTs was 4.3%, it ranged from 0-16%. Zero consent declines were seen in one vaccine RCT among the 39 studies.[7] This indicates either desperation or therapeutic misconception as a possible cause. Contrary to this, Li et al.,[20] in a phase 1 trial (China, single centre) for a vaccine during Ebola epidemic found 11% consent declines and 8.4% consent withdrawals after booster vaccination. This highlights the distinction between consent declines in vaccine studies in a pandemic versus an epidemic setting.

The COVID-19 RCT with the highest consent decline rate (16%) was the use of Hydrocortisone as treatment for severe COVID-19 hospitalized patients.[17] This was a multi-centric RCT in several countries where one arm was local standard of care which did not include hydrocortisone. This potentially could have accounted for the higher consent decline rate seen. Another RCT had a 5% consent decline rate and this was the use of HCQ as post-exposure prophylaxis among participants who had either household or occupational exposure to a confirmed COVID-19 person.[9] This is only slightly higher than the average consent decline rate of 4.3% and could be due to the fact that the efficacy of HCQ was frequently questioned both in scientific literature and the lay press.

The present study showed a lower consent withdrawal rate in standard of care/best supportive care arm than in interventional arm in COVID-19 RCTs. One amongst few reasons for this may have been participant's refusal for diagnostic tests and investigations in the interventional arm which needed to be done multiple times. The uncertainty or psychological distress surrounding the pandemic could also have led to participant's withdrawal from the study.[21]

Our study has several limitations. First, it has focused only on English language RCTs published in PubMed/Medline. Secondly, a large number of COVID-19 and non-COVID-19 RCTs that did not satisfy the selection criteria were excluded. Third, whether the participant themselves or their LARs declined or withdrew consent is a surmise but the data is not given in the publications. Fourthly, we did not have data on consent withdrawals in the historical controls and hence the comparison was not done. Finally, the data on impact of co-variates such as economic status of the country and age of patients on consent declines and consent withdrawals was not available.

In summary, the present study shows a significantly lower rate of consent declines in COVID-19 RCTs relative to non-COVID-19 RCTs during a pandemic setting. The findings were also similar for RCTs conducted in a pandemic setting when compared with a non-pandemic setting. The physicians who undertake studies should spend more time on the informed consent process to prevent or minimize therapeutic misconceptions during the pandemic so as to ensure adequate participant understanding and comprehension.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1U.S. Department of Health and Human Services.gov [Internet]. The Belmont Report: Ethical principles and Guidelines for the protection of Human Subjects of Research [Last reviewed 2018 Jan 15]. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html. [Last accessed on 2020 Dec 10].
2Figer BH, Thaker SJ, Boob M, Gogtay NJ, Thatte UM. An evaluation of reporting of consent declines in three high impact factor journals. Clin Ethics 2018;13:189-93.
3Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in non-hospitalized adults with early COVID-19. Ann Intern Med 2020;173:623-31.
4Furtado RHM, Berwanger O, Fonseca HA, Correa TD, Ferraz LR, Lapa GM, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): A randomised clinical trial. Lancet 2020;396:959-67.
5Spinner CD, Gottlieb RL, Criner GJ, Lopez JRA, Cattelan AM, Viladomiu AS, et al. Effect of Remdesivir vs Standard Care on clinical status at 11 days in patients with moderate COVID-19-A randomized clinical trial. JAMA 2020;324:1048-57.
6Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787-99.
7Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78.
8Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo controlled, phase 2 trial. Lancet 2020;396:479-88.
9Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383:517-25.
10Bierer BE, White SA, Barnes JM, Gelinas L. Ethical challenges in clinical research during the COVID-19 pandemic. J Bioeth Inq 2020;17:717-22.
11Baillie C. Antenatal screening. BMJ 1999;318:805.
12Edwards SJ. Research participation and right to withdraw. Bioethics 2005;19:112-30.
13COVID-19 Treatment Guidelines.nih.gov [Internet]. Clinical Spectrum of SARS-CoV-2 Infection [Last reviewed 2020 Dec 2017]. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinicalspectrum/#:~:text=Patients%20with%20COVID%2D19%20are, or%20lung%20infiltrates%20%3E50%25. [Last accessed on 2021 Apr 02].
14Thaker SJ, Figer BH, Gogtay NJ, Thatte UM. An audit of consent refusals in clinical research at a tertiary care center in India. J Postgrad Med 2015;61:257-63.
15Castillo ME, Costa LME, Barrios JMV, Diaz JMA, Miranda JL, Bouillon R, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol 2020;203:105751.
16Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ 2020;369:m1849.
17Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020;324:1317-29.
18Cusinato J, Cau Y, Calvani AM, Mori M. Repurposing drugs for the management of COVID-19. Expert Opin Ther Pat 2020;31:295-307.
19Sayad B, Sobhani M, Khodarahmi R. Sofosbuvir as repurposed antiviral drug against COVID-19: Why were we convinced to evaluate the drug in a registered/approved clinical trial? Arch Med Res 2020;51:577-81.
20Li JX, Hou LH, Meng FY, Wu SP, Hu YM, Liang Q, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: Final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2017;5:e324-34.
21Del Brutto OH, Castillo PR, Sedler MJ, Del Brutto VJ, Zambrano M, Mera RM, et al. Reasons for declining consent in a population-based cohort study conducted in a rural South American Community. J Environ Public Health 2018;2018:8267948.

 
Wednesday, June 29, 2022
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer